HANMI PHARM.
HANMI PHARM, officially known as Hanmi Pharmaceutical Co., Ltd., is a leading player in the global pharmaceutical industry, headquartered in KP. Established in 1973, the company has made significant strides in research and development, particularly in the fields of oncology, diabetes, and autoimmune diseases. With a strong presence in both domestic and international markets, HANMI PHARM is renowned for its innovative drug formulations and advanced biopharmaceuticals. Their core products, including unique oral medications and biologics, set them apart through their efficacy and safety profiles. Recognised for its commitment to quality and innovation, HANMI PHARM has achieved notable milestones, including strategic partnerships and successful product launches that enhance its market position. As a forward-thinking organisation, it continues to contribute to the advancement of healthcare solutions worldwide.
DitchCarbon Score
How does HANMI PHARM.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HANMI PHARM.'s score of 32 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HANMI PHARM.'s reported carbon emissions
In 2023, HANMI PHARM. reported total carbon emissions of approximately 11520000 kg CO2e for Scope 1, 49719000 kg CO2e for Scope 2, and 82555000 kg CO2e for Scope 3, resulting in a combined total of about 123390000 kg CO2e. The Scope 1 emissions primarily stemmed from stationary combustion, accounting for about 10983000 kg CO2e. The company has shown a commitment to transparency by disclosing emissions across all three scopes. Comparatively, in 2022, HANMI PHARM. recorded Scope 1 emissions of about 10762000 kg CO2e and Scope 2 emissions of approximately 49358000 kg CO2e, leading to a total of around 60118000 kg CO2e for Scope 1 and 2 combined. This indicates a slight increase in emissions in 2023, particularly in Scope 2. Despite the increase in emissions, there are currently no specific reduction targets or climate pledges documented for HANMI PHARM. The company has not cascaded any emissions data from a parent or related organization, indicating that all reported figures are derived directly from its own operations. Overall, HANMI PHARM. is actively monitoring its carbon footprint, but further commitments to reduction initiatives or targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 13,523,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 58,287,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
HANMI PHARM. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
